151 related articles for article (PubMed ID: 35032505)
1. Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
Arnaud A; Bonthapally V
J Affect Disord; 2022 Mar; 301():445-447. PubMed ID: 35032505
[No Abstract] [Full Text] [Related]
2. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
[TBL] [Abstract][Full Text] [Related]
5. Zuranolone: First Approval.
Heo YA
Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
[TBL] [Abstract][Full Text] [Related]
6. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
[TBL] [Abstract][Full Text] [Related]
7. New depression drug zuranolone one step closer to FDA ruling.
Carvalho T
Nat Med; 2023 May; 29(5):1032-1033. PubMed ID: 37041352
[No Abstract] [Full Text] [Related]
8. Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
Ten Doesschate F; van Waarde JA; van Wingen GA
J Affect Disord; 2022 Sep; 313():149-150. PubMed ID: 35780962
[No Abstract] [Full Text] [Related]
9. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
Bullock A; Kaul I; Li S; Silber C; Doherty J; Kanes SJ
J Neurol Sci; 2021 Feb; 421():117277. PubMed ID: 33387701
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
Bullock A; Gunduz-Bruce H; Zammit GK; Qin M; Li H; Sankoh AJ; Silber C; Kanes SJ; Jonas J; Doherty J
Hum Psychopharmacol; 2022 Jan; 37(1):e2806. PubMed ID: 34352138
[TBL] [Abstract][Full Text] [Related]
11. Non-superiority of zuranolone (SAGE-217) at the longer-term.
Ten Doesschate F; van Waarde JA; van Wingen GA
J Affect Disord; 2021 Aug; 291():329-330. PubMed ID: 34082218
[No Abstract] [Full Text] [Related]
12. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
[TBL] [Abstract][Full Text] [Related]
14. Concerns That May Limit the Utility of Zuranolone.
Prasad V; Allely D
JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
Frieder A; Fersh M; Hainline R; Deligiannidis KM
CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
[TBL] [Abstract][Full Text] [Related]
16. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
Cerbo AD
Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.
Eser D; Schüle C; Romeo E; Baghai TC; di Michele F; Pasini A; Zwanzger P; Padberg F; Rupprecht R
Psychopharmacology (Berl); 2006 Jun; 186(3):373-87. PubMed ID: 16247651
[TBL] [Abstract][Full Text] [Related]
18. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
[TBL] [Abstract][Full Text] [Related]
19. Trial of SAGE-217 in Patients with Major Depressive Disorder.
Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
[TBL] [Abstract][Full Text] [Related]
20. Development of neuroactive steroids for the treatment of postpartum depression.
Gunduz-Bruce H; Takahashi K; Huang MY
J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
